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We report here on a chemical genetic screen designed to address the mechanism of action of a small molecule. Small
molecules that were active in models of urinary incontinence were tested on the nematode Caenorhabditis elegans, and
the resulting phenotypes were used as readouts in a genetic screen to identify possible molecular targets. The
mutations giving resistance to compound were found to affect members of the RGS protein/G-protein complex. Studies
in mammalian systems confirmed that the small molecules inhibit muscarinic G-protein coupled receptor (GPCR)
signaling involving G-aq (G-protein alpha subunit). Our studies suggest that the small molecules act at the level of the
RGS/G-aq signaling complex, and define new mutations in both RGS and G-aq, including a unique hypo-adapation
allele of G-aq. These findings suggest that therapeutics targeted to downstream components of GPCR signaling may be
effective for treatment of diseases involving inappropriate receptor activation.
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Introduction
Urinary incontinence (UI) is an increasing medical prob-
lem in ageing populations. Affecting more than 12 million
afﬂicted people in the US alone, UI is a frequent cause of
conﬁnement and lifestyle modiﬁcation [1]. UI is deﬁned as
the involuntary loss of urine, and may result from a number
of causes including the improper control of detrusor activity
or compromised urethral function. UI can also occur as a
complication of other diseases such as Parkinson disease,
multiple sclerosis, and bladder infections, indicating that
there are both muscular and neuronal components of the
disease.
Current treatments for UI rely on antagonism of G-protein
coupled receptors (GPCRs) of the muscarinic acetylcholine
receptor class [2]. The signal transduction pathways down-
stream of muscarinic GPCRs are responsible for bladder
muscle cell contractility, and antagonists of these receptors
allow for greater bladder ﬁlling. While muscarinic GPCR
antagonists are generally safe, they have unwanted side effects
due to the broad tissue expression of their targets [3–5].
GPCRs are the most successful class of targets for disease
states including hypertension, diabetes, obesity, depression,
osteoporosis, and inﬂammation. In fact, more than half of
currently marketed drugs for the condition act as modulators
of this protein class [6,7]. Methods to modulate other
signaling nodes downstream of GPCRs may hold potential
for safer and more efﬁcacious therapies.
Heterotrimeric G-proteins are the proximal signaling
partners downstream of GPCRs. Binding of acetylcholine to
the muscarinic GPCRs results in the exchange of GDP for
GTP on the G-protein a subunit (G-aq). This activation event
allows dissociation of G-aq from the G-b/c heterodimer. The
dissociated G-protein subunits then mediate separate cellular
responses through their interactions with enzymes, channels,
kinase cascades, and intracellular second messengers [8–10].
In smooth muscle cells, activation of G-aq results in protein
kinase C (PKC)-dependent calcium mobilization and subse-
quent muscle contraction. Following GTP hydrolysis on G-a,
the heterotrimeric G-protein complex reforms and signaling
is terminated. G-protein function is under the strict control
of factors such as the regulators of G-protein signaling (RGS)
proteins. RGS proteins were ﬁrst identiﬁed as potent negative
regulators of GPCR signaling in yeast [11], and are now
known to act as GTPase activating proteins (GAPs) in all
eukaryotic systems. RGS proteins bind directly to the G-a
subunit and enhance the rate of GTP hydrolysis, thereby
shortening the lifetime of the dissociated, active G-protein
species and curtailing GPCR signaling [12]. At least 24
mammalian proteins contain a common ‘‘RGS core domain’’
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have spatially restricted expression patterns, suggesting that
they may allow tissue-speciﬁc control of ubiquitous G-
proteins [14,15].
In this paper we describe mechanism-of-action studies with
small molecules that were originally identiﬁed by their
activity in an ex vivo bladder contraction assay. These effects
are mediated by a heretofore unknown molecular mechanism
[16]. Notably, in vivo studies using a selected example (BMS-
195270) revealed that this small molecule displayed marked
tissue speciﬁcity, inhibiting bladder contractility at doses that
did not signiﬁcantly affect blood pressure or heart rate [16]
(unpublished data). To deﬁne the pathway of action of these
small molecules, we have used genetic screens in Caenorhabditis
elegans coupled with biochemical assays in mammalian
systems. We demonstrate that these small molecules likely
act at the intersection of RGS and G-aq proteins, resulting in
the downregulation of GPCR signaling, reduced calcium
ﬂuxes, and reduced muscle contraction. In addition, we have
uncovered novel mutations in RGS and G-aq proteins,
including the ﬁrst hypo-adaptation allele of a G-aq protein.
Identiﬁcation of a novel set of compounds that function to
limit signaling downstream of GPCRs, as well as a hypo-
adapation allele of G-aq, has implications for the many
diseases currently treated via direct modulation of these
receptors.
Results
Small Molecules That Affect Mammalian Rat Bladder
Muscle Contraction via an Unknown Mechanism
Several related small molecules (Figure 1) were identiﬁed as
active in a screen for inhibition of carbachol-evoked tonicity
of isolated rat bladder strips. The effects of BMS-195270 in an
ex vivo rat whole bladder model are shown in Figure 2.
Typical cystometric curves (bladder pressure plotted versus
infused volume) for BMS-195270–treated or vehicle-treated
bladders are shown in Figure 2A and Figure 2B. Incubation of
bladders in BMS-195270 produced a dramatic reduction in
developed pressure at infusion volumes of 0.2–1.3 mls (Figure
2A; n ¼ 5, p , 0.05) relative to the vehicle-only treatments
over the same ﬁlling volume range (Figure 2B; n ¼ 12
bladders). BMS-195270 treatment was also found to inhibit
‘‘spontaneous’’ contractions (Figure 2C and 2D). The ﬁnding
that BMS-195270 was able to increase the ﬁlling capacity and
reduce spontaneous contractions in this ex vivo model
underscored the potential utility of this class of small
molecules in treating UI resulting from overactive bladder
contractions. Assays of structurally related small molecules
revealed two small-molecule pairs that each contain one
active and one inactive small molecule (BMS-192364/BMS-
192365 and BMS-195270/BMS-195243; Figure 1A–1D, [16]).
The mechanism of this bladder-speciﬁc activity, however, was
not known.
A Chemical Genetic Approach in C. elegans to Identify
Candidate Targets
We next utilized C. elegans to elucidate the molecular
pathway affected by these small molecules. First, the active
small molecules BMS-192364 and BMS-195270 were applied
to wild-type adult C. elegans, and the resulting phenotypes
observed (see Materials and Methods). Note that treatment of
C. elegans with small molecules typically requires a higher
concentration than cell-based assays, due to the worms’
relatively impermeable cuticle.
Treatment of adult worms with 0.3 mM BMS-192364
resulted in a bloated egg-laying defective (Egl-d) phenotype
that included retention of fertilized late-stage eggs (Figure
3A). This Egl-d phenotype indicates defective neuromuscular
function in the egg-laying process. Treatment with BMS-
192364 is dose-responsive, with a cumulative total of .90%
of animals ultimately displaying an Egl-d phenotype (Figure
3B). Treatment of adult worms with BMS-195270 at 2.8 mM
resulted in a similar Egl-d phenotype, as well as slowed or
arrested pharyngeal pumping (Eat), and uncoordinated
motion (Unc). These phenotypes also indicate a defect in
Figure 1. Structure and Activity of BMS Small Molecules
The effect of each compound on inhibition of carbachol-evoked tonicity
of isolated rat bladder strips is shown in the table.
DOI: 10.1371/journal.pgen.0020057.g001
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Synopsis
The authors have utilized Caenorhabditis elegans, and yeast genetics,
combined with mammalian tissue and cell culture experiments to
investigate the mechanism of action of a unique set of small
molecules. These molecules are active in tissue models of urinary
incontinence and allow for increased bladder filling. In the course of
studying sensitivity and resistance to these compounds, Fitzgerald
et al. uncovered novel alleles of RGS and Gq proteins. Further
characterization of one such allele identified that its action conferred
a hypo-adaptive phenotype on yeast during pheromone signaling
assays. Their data as a whole indicate that these small molecules are
able to diminish signaling from G-protein coupled receptors (GPCR)
downstream of the receptors themselves. Since GPCR signaling is
very important in many diseases in humans, the novel mechanism of
these compounds may offer new ways to treat human disease.normal neuromuscular signals. The pumping and movement
defects were apparent within two hours of treatment, and the
Egl-d phenotype was noted within 12 hours of treatment and
maximal after 24 hours, consistent with an acute effect on the
neuromuscular system. Structurally related small molecules
that lacked the bladder-relaxing activity, such as BMS-192365,
did not cause the Egl-d, Eat, or Unc phenotypes under any
treatment conditions (unpublished data). This observation
suggested that the structure–activity relationship as deter-
mined in the mammalian systems held true in C. elegans, and
that the worm phenotypes corresponded to the therapeutic
activity of the compounds. BMS-192364 was the more potent
of the two active molecules in the egg-laying assays, and
subsequent analyses in C. elegans used this compound.
To identify potential molecular targets or target pathway
components for the small molecules, we ﬁrst took a
candidate-gene approach. The G-protein mediated pathways
involved in egg laying have been extensively characterized in
C. elegans. We tested BMS-192364 on 27 different worm
strains, each carrying a mutation in pathways implicated in
egg laying (Table 1). Of the 27 strains tested, three exhibited
at least partial resistance to the Egl-d phenotype induced by
BMS-192364. (Resistance was deﬁned as no more than 15% of
animals exhibiting an Egl-d phenotype in the presence of a
small-molecule dose which renders .90% of wild-type
animals Egl-d). The three resistant strains carried either the
eat-16(ad702), the egl-19(n582ad952), or the egl-19(n2361)
mutation.
Interestingly, the mutation giving rise to the strongest
resistance phenotype, eat-16(ad702), disrupts an mRNA splice
acceptor site and leads to truncation of an RGS protein. The
EAT-16 RGS protein would normally downregulate G-protein
signaling, an activity consistent with the phenotype of the
small molecule [17]. The nIS51(egl-10þ) allele phenotypically
resembles the eat-16(ad702) allele (it overexpresses the EGL-10
RGS protein, which acts in an antagonistic pathway).
However while the eat-16(ad702) strain was resistant to BMS-
192364, a strain carrying the egl-10(nIS51) allele showed no
resistance. Thus the resistance of the eat-16(ad702) strain
seems closely linked to EAT-16 signaling status. In addition,
the lack of resistance or hypersensitivity exhibited by strains
carrying mutations in egl-8, dgk-1, tpa-1, or unc-68 (encoding
phospholipase C, diacylglycerol kinase, PKC, and the Ryano-
dine receptor; Table 1) indicated that BMS-192364 was most
likely acting upstream of or parallel to these genes’ products.
Taken together, the candidate-gene results suggested a target
function in the area of the neurotransmitter/GPCR/G-protein
complex. The resistance exhibited by two strains carrying
gain-of-function mutations in egl-19 [18] also indicated that
calcium channels could be the target of BMS-192364.
Genetic screens designed to identify both dominant and
recessive mutations have been used successfully to identify
Figure 2. Effect of BMS Small Molecules in Ex Vivo Whole-Bladder Assays
Bladder pressure was monitored during saline infusion in the presence of BMS-195270 or vehicle. A typical cystometric curve shows three phases: a
small rapid rise in intravesical pressure followed by a plateau phase and then a final sharp increase in pressure.
(A) Bladder pressure following treatment with BMS-195270 (3 lM; n ¼ 5 bladders). The average pressure at discrete infusion volumes is shown.
Significant differences in pressure relative to control (p , 0.05) are indicated by asterisks.
(B) Bladder pressure following treatment with vehicle (n ¼ 12 bladders). The average pressure at discrete infusion volumes is shown. No difference in
pressure relative to control was seen.
(C) Representative trace from vehicle-treated bladder, showing magnitude of spontaneous contractions developed during saline infusion.
(D) Representative trace from bladder treated with BMS-195270 (3 lM), showing reduction in frequency and magnitude of spontaneous contractions
developed during saline infusion.
DOI: 10.1371/journal.pgen.0020057.g002
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RGS/G-Protein Role in Action of a CompoundFigure 3. Effect of Small Molecules on Wild-Type and Mutant C. elegans
(A) The gonad/vulval region of wild-type worms is shown. In the left panel, black arrows indicate the normal, organized array of early stage eggs. The
right panel shows a worm treated with BMS-192364 at 0.3 mM. The white arrows indicate late stage eggs that have been retained in the gonad.
(B) Dose-response curve for BMS-192364, showing effect on egg laying in C. elegans. The percentage of worms displaying an Egl-d phenotype was
determined by counting the number of ‘‘commas’’ contained within the animal.
(C) Quantification of the Egl-d phenotype in four C. elegans mutant strains—ep271, ep272, ep273, and ep275—that were identified in a screen for
resistance to the small molecule. Black bars, no treatment. Grey bars, worms treated with BMS-192364 at 0.4 mM.
(D) Table showing identity of the affected gene in C. elegans–resistant mutant strains, the amino acid changes, and predicted effect on protein function.
DOI: 10.1371/journal.pgen.0020057.g003
Table 1. Description of C. elegans Mutant Alleles Used
Gene Allele Protein Type Function Status Compound Effect Accession Number
egl-30 n683 G-aq Loss Sensitive NM_001026403
egl-30 pk931 G-aq Gain Sensitive NM_001026403
egl-8 n488 Phospholipase C Loss Sensitive AF179426
tpa-1 k501 PKC Loss Sensitive NM_067459
goa-1 n363 G-a0 Loss Sensitive NM_059707
dgk-1 sy428 DAG loss Sensitive NM_001029213
eat-16 ad702 RGS protein Loss Resistant NM_170912
egl-10 n151 RGS protein Gain Sensitive NM_073724
egl-19 (n582ad952) L/N type calcium channel Gain Resistant NM_171379
egl-19 n2368 L/N type calcium channel Gain Resistant NM_171379
unc-2 e55 Calcium channel Loss Sensitive NM_171638
unc-36 e251 Calcium channel Loss Sensitive NM_066388
unc-68 E540 Ryanodine receptor Loss Sensitive NM_072352
itr-1 sa73 INsP3R Loss Sensitive NM_001028003
sup-9 n1435 TWIK channel Loss Sensitive NM_061932
unc-110 e2383 TWIK channel Loss Sensitive
unc-110 e1913 TWIK channel Gain Sensitive
unc-103 n1211 HERG channel Loss Sensitive NM_065423
unc-103 e1597 HERG channel Gain Sensitive NM_065423
egl-2 sa236 EAG channel Loss Sensitive NM_071001
egl-2 n693 EAG-channel Gain Sensitive NM_071001
egl-36 sa630 SHAW channel Loss Sensitive NM_077394
egl-36 n728 SHAW channel Gain Sensitive NM_077394
exp-2 ad1426 Spike channel Loss Sensitive NM_001028619
avr-15 ad1501 Glu-gated channel Loss Sensitive NM_001028905
unc-43 n1186 CAMKII Loss Sensitive NM_001028122
unc-43 N498 CAMKII Gain Sensitive NM_001028122
Bolded items are the only resistant ones.
DOI: 10.1371/journal.pgen.0020057.t001
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In parallel to the candidate gene analysis, we also decided to
carry out an unbiased genetic screen based on the robust Egl-
d phenotype, looking for resistance to the small molecule
BMS-192364. The candidate gene analysis indicated that such
a screen should yield resistant mutants. 150,000 EMS-
mutagenized genomes were generated and screened, resulting
in the identiﬁcation of four resistant mutants (Figure 3 C). In
all cases these mutants were egg-laying constitutive (Egl-c) in
the absence of treatment, and both the Egl-c phenotype and
the drug resistance were dominant or semidominant. All
BMS-192364–resistant mutants were also found to be cross-
resistant to the phenotypes induced by BMS-195270 (unpub-
lished data).
Dominant C. elegans–Resistant Mutations Affect G-Protein
Pathway Components
The mutations present in the three resistant strains ep271,
ep273, and ep275 were mapped to deﬁned chromosomal
regions using recombinant single nucleotide polymorphism
(SNP) techniques [21,22]. Genes in these regions that were
known to confer an Egl-c phenotype were obvious candidates.
Linkage tests to known alleles, and direct sequence analysis,
showed that three of the four mutated genes were allelic to
the known genes egl-30, eat-16, and goa-1 (Figure 3D). The
identity of the gene affected in the fourth resistant strain,
ep272, remains unknown.
Strain ep271 carried a mutation in egl-30, which encodes the
worm ortholog of the G-aq subunit and is required for egg
laying [17,23]. Based on the Egl-c mutant phenotype observed,
the mutation found in the egl-30(ep271) allele, M244I, is
predicted to constitutively activate G-aq signaling. Methio-
nine-244 of EGL-30 is conserved in many G-proteins that are
regulated by an RGS domain–containing protein (Figure 4A).
Strain ep273 carried a mutation in eat-16, a member of the
conserved RGS protein family [17]. EAT-16 has been shown to
directly interact with and negatively regulate signaling via the
G-aq protein EGL-30 [17,24,25]. The eat-16(ep273) allele was
found to generate a nonconservative change, E158K, at a
location between the DEP and GGL regions of the protein
(Figure 4B). The Egl-c phenotype of the eat-16(ep273) mutant
is similar to known loss-of-function eat-16 mutants [17,24].
Strain ep275 carried a mutation in goa-1 [17,26], which
encodes the worm G-ao protein and acts to negatively
regulate egg laying, most likely acting in parallel to the egl-
30/eat-16 pathway [23,27]. The goa-1(ep275) allele was found to
contain a stop codon that truncates the GOA-1 protein at
amino acid 205, and is predicted to produce an inactive
protein (Figure 3D).
The results of the genetic screen were striking. All three of
the cloned resistant alleles (two dominant and one semi-
dominant) affect proteins that are members of G-a/RGS
complexes. This result, combined with the candidate gene
analysis (Table 1), indicated that the small molecules were
most likely acting on the signaling pathway at the level of the
G-protein complexes. To summarize the genetic results, we
observed two strongly compound resistant loss-of-function
(lf) alleles of eat-16, one resistant and one sensitive gain-of-
function (gf) allele in egl-30, and one resistant and one
sensitive (lf) allele in goa-1, and ﬁnally two resistant (gf) alleles
of egl-19, which encodes an L-type calcium channel [18]. The
location of these gene products in a canonical signaling
pathway is shown in Figure 5. In both the candidate gene
analysis and the genetic screen, the strongest resistance was
displayed by eat-16 (lf) alleles. The differential resistance of
the egl-30(ep271) and egl-30(pk931) strains (Figure 4C) was
quite surprising, as without compound treatment they display
an identical Egl-c (gf) phenotype. This might indicate that
these alleles have obtained their gain-of-function properties
through different mechanisms: the egl-30(pk931) allele was
originally identiﬁed as a suppressor of gpb-2 overexpression
phenotypes (RP, personal communication).
Confirmation of G-Protein Involvement Using a
Mammalian System
The functional roles of the C. elegans modiﬁer genes
pointed us toward a small-molecule mechanism involving
calcium signaling via G-proteins (Figure 5). To validate and
extend this model in mammalian cells, the small molecules
were evaluated for their effects on muscarinic GPCR-
mediated calcium release in mammalian cells. Both BMS-
192364 and BMS-195270 inhibited the response of HEK293
cells to the muscarinic agonist carbachol (Figure 6A and 6B;
the EC50 for BMS-192364 was 9 lM, and for BMS-195270 was
Figure 4. Protein Mutants Identified and Epistasis Tests
(A) Alignment of a region of EGL-30 containing the M244I amino acid
substitution with other G-proteins. The conserved methionine residue
that is mutated to isoleucine in the egl-30(ep271) allele is indicated in
bold text and underlined.
(B) Diagram showing the domain structure of the EAT-16 protein with
relative locations of the E158K substitution found in the eat-16(ep273)
allele, and the splice site mutation found in eat16(ad702) strains.
(C) Genetic interactions between mutations in G-aq and RGS. The G-aq/
egl-30(ep271) and RGS/eat-16(ad702) mutations confer resistance to BMS-
192364. The sensitivity of a G-aq/egl-30(pk931) strain to BMS-192364 is
abrogated in the presence of the eat-16(ad702) mutation.
DOI: 10.1371/journal.pgen.0020057.g004
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inhibitors indicated that the majority of the carbachol-
evoked signal was via muscarinic receptor type 3 (M3), with
a small amount via M2 (unpublished data). The degree of
inhibition observed with BMS-192364 and BMS-195270 was
similar to that seen with known pan-muscarinic receptor
inhibitors. The ability of the small molecules to inhibit
calcium ﬂuxes downstream of muscarinic receptor activation
was entirely consistent with our observations in mammalian
bladder tissue and C. elegans.
Utilizing a primary bladder smooth muscle cell line with
Histamine as a receptor agonist, we also observed inhibition
of calcium ﬂux by BMS-192364 (Figure 6C) and BMS-195270
(unpublished data). Our genetic results had suggested that the
compounds acted downstream of muscarinic receptors. To
further investigate this, we carried out competitive binding
assays with BMS-192364 and the radio-labeled muscarinic
ligand N-methylscopolamine. We observed no effect on
radio-ligand binding to the muscarinic receptor types M1–5
[28,29] using BMS-192364 at concentrations of 10lM. Similar
radio-ligand binding experiments with the histamine recep-
tors H1–4 were also negative (unpublished data) [30–32].
While we can not rule out the existence of a previously
undescribed allosteric site shared by the two GPCR types,
from these results it is unlikely that BMS-192364 and related
small molecules act directly on muscarinic or histamine
receptors. Additional BMS compound/radio-ligand binding
assays run on adrenergic, angiotensin, bradykinin, cannabi-
noid, dopamine, endothelin, neuropeptide Y, nicotinic,
serotonin, and other GPCRs were also negative.
The mammalian N- and L-type calcium channels were also
of interest as potential targets, due to the partial resistance
exhibited by two egl-19(gf) alleles in C. elegans (Table 1). To
address the possibility that BMS-192364 and BMS-195270
were acting directly on the channels, we repeated the
carbachol-stimulated Ca-ﬂux assays, but pretreated cells with
a high concentration of the calcium channel blocker
niguldipine [33]. We reasoned that if BMS-195270 were
acting directly on calcium channels, by preblocking those
channels with niguldipine, we should observe no further
effect of BMS-195270 on calcium ﬂux. We observed that while
pretreatment with niguldipine slightly dampened carbachol-
induced calcium ﬂux, BMS-195270 treatment was clearly
additive to this effect (Figure 7A). This additive response
indicated that BMS-195270 retained inhibitory activity even
when endogenous calcium channels were inactivated. In
addition to the cellular assays, competitive binding assays
were performed using radio-labeled diltiazem (L-type ligand)
[30] or x-conotoxin (N-type ligand) [34]. BMS-192364 at 10lM
had no effect on binding of either radio-ligand, suggesting
that the L- and N-type channels are not the direct target of
BMS-192364.
Our genetic analysis for resistance to BMS-192364 had
identiﬁed multiple alleles affecting the RGS protein EAT-16
and single alleles for G-aq (egl-30) and G-a0 (goa-1). The
genetic data also indicated that the targeted process was
likely upstream or parallel to PKC (tpa-1), PLC (egl-8), DGK
(dgk-1), and the RyR (unc-68), as mutations in these genes did
not affect sensitivity to BMS-195270 (Table 1). Clearly a
comprehensive analysis of potential branched effecter path-
ways needs to be carried out. Consistent with these genetic
observations, pretreatment of HEK293 cells with inhibitors of
the ryanodine receptor (ryanodine), PI3-kinase (wortmanin),
or PLC (U73122) did not affect inhibition of carbachol-
induced calcium ﬂux by BMS-195270 (unpublished data).
Therefore, we next examined the G-protein/RGS complex
more closely.
In C. elegans, the RGS protein EAT-16 has been shown to
interact with both G-aq/EGL-30 and G-a0/GOA-1, in different
complexes. Therefore, we investigated which G-a subunit was
involved in the BMS-195270 activity seen in HEK293 cells.
Given that the muscarinic receptor M3 (a G-aq–coupled
receptor) was responsible for the majority of the carbachol-
induced signal, G-aq was the most likely candidate. We tested
the effects of BMS-195270 in combination with pertussis
toxin, which is a known blocker of G-ao/i and G-as signaling
but does not affect G-aq [35]. Pertussis toxin has been utilized
extensively to differentiate G-a signals. Pertussis toxin
Figure 5. Analysis of Molecular Signaling Events Controlling Muscular Contraction in C. elegans
The diagram shows the molecular components of the signaling pathways downstream of the muscarinic GPCRs in C. elegans. Alleles of genes encoding
proteins in the pathway were tested for their effect on the Egl-d phenotype caused by treatment with BMS-192364. For the pathway members
indicated by stars, certain alleles altered the response to treatment with BMS-192364. Specifically, resistance to the Egl-d phenotype was conferred by
two gain-of-function alleles of egl-19 and one of egl-30, and by two loss-of-function alleles of eat-16 and one of goa-1.
DOI: 10.1371/journal.pgen.0020057.g005
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ulation of HEK293 cells, but the effect of pertussis toxin was
nearly additive with that of BMS-195270 (Figure 7B). This
result indicated that BMS-195270 inhibits signaling down-
stream of muscarinic receptors, at least in part, by a G-aq-
dependent mechanism. This observation was entirely con-
sistent with the genetic analysis in C. elegans, but does not
exclude the possibility that some BMS-195270 activity in
Figure 7. Effect of BMS-192364 in Combination with Other Modulators of
Calcium Signaling
The graphs display fluorescence intensity measurements for HEK293 cells
preloaded with Fluo-4 then stimulated with the muscarinic GPCR agonist
carbachol at 100 lM. Five baseline fluorescence measurements were
taken prior to the injection of carbachol. Where indicated, BMS-195270
or BMS-192364 (100 lM) were added 15 min prior to the carbachol
stimulation. The timing of carbachol addition is indicated by a black
arrowhead.
(A) Where indicated, cells were pre-incubated for 15 min with the
calcium channel blocker niguldipine (100 lM).
(B) Where indicated, cells were pre-incubated for 24 h with the G-protein
antagonist pertussis toxin (150 ng/ml).
(C) The treated cells are overexpressing the G-aq mutant allele G188S,
which is known to be insensitive to RGS GAP activity.
DOI: 10.1371/journal.pgen.0020057.g007
Figure 6. Effect of Compounds on Agonist-Induced Calcium Flux
(A) The graph displays fluorescence intensity measurements for HEK293
cells preloaded with Fluo-4. Five baseline fluorescence measurements
were taken prior to the injection of the muscarinic GPCR agonist
carbachol. The timing of agonist addition is indicated by a black
arrowhead. Measurements were performed in the presence of vehicle or
the BMS small molecules indicated, at 100 lM.
(B) Dose-response analysis for the effect of compounds on carbachol-
stimulated calcium flux. White squares, BMS-195270; EC50 2 lM. Black
squares, BMS-192364; EC50 9 lM.
(C) The graph displays fluorescence intensity measurements for primary
smooth muscle cells preloaded with Fluo-4. Five baseline fluorescence
measurements were taken prior to the injection of the GPCR agonist
histamine. The timing of agonist addition is indicated by a black
arrowhead. Measurements were performed in the presence of vehicle or
BMS-192364 (100 lM).
DOI: 10.1371/journal.pgen.0020057.g006
PLoS Genetics | www.plosgenetics.org April 2006 | Volume 2 | Issue 4 | e57 0431
RGS/G-Protein Role in Action of a Compoundmammalian cells might also be due to inhibition of another
G-a subtype activity.
Genetic Tests Differentiate between Models of Small-
Molecule Action
The biochemical and genetic data collectively directed us
toward a hypothesis that the BMS small molecules affect the
RGS/G-protein complex. In simple, single-target models, the
behavior of BMS-192364 and BMS-195270 is consistent with
action as an RGS protein agonist, or as a G-a antagonist. In the
former model, the small molecule would increase the rate at
which RGS protein is able to stimulate GTP catalysis by G-a
(RGSGAPactivity)and therebyshorten theactive periodof G-
protein signaling. In the latter model, the small molecule
inhibits G-aq activity directly. The small molecule could affect
the activation of G-aq or its ability to signal to downstream
partners (Figure 8). A precedent for small-molecule effects on
G-aq has been set by YM-254890 [36], which has been reported
to inhibit the activity of G-aq. Genetic tests in a variety of
systemswereusedtoinvestigatethesetwosingle-targetmodels.
A Genetic Test of the RGS Agonist Model in Yeast
If the compounds act via the RGS protein, G-aq proteins
that are resistant to RGS GAP activity should also exhibit
resistancetothecompound.InC.eleganstheegl-30(ep271)allele
of G-aq, which contains the amino acid substitution M244I,
confers resistance to compound BMS-192364. Therefore, we
wished to determine whether this mutation also confers
resistance to RGS GAP activity, as predicted by the ﬁrst model.
Ideally, resistance to compound activity and to RGS GAP
activity should be studied in the same genetic system.
However, there are no C. elegans strains that carry bichemi-
cally proven RGS GAP–insensitive alleles of G-a, and there is
no system for evaluating response to RGS GAP activity in C.
elegans. Instead, RGS GAP activity is studied in the yeast
Saccharomyces cerevisiae, which offers both a robust assay system
and also the ability to substitute the mutant alleles under
analysis [11,37]. (Unfortunately, the insolubility of compound
BMS-192364 in yeast growth media prohibits direct evalua-
tion of its action in yeast). The yeast RGS/G-a interaction is
highly conserved with respect to higher eukaryotes, and the
resistance of a mammalian G-a mutant protein to RGS GAP
activity has been determined in this system [11,37]. Therefore,
observations in yeast will be informative as to the properties
of the C. elegans egl-30(ep271) allele.
RGS/G-a interactions in yeast are evaluated by treatment
with the peptide ligand a–factor, which acts on the GPCR
Ste2 initiating a signaling cascade that blocks cell division.
This can easily be assayed as a halo of growth arrest around a
point source of the ligand (Figure 9A) [11,38–42]. In the
absence of the GAP activity of yeast RGS protein Sst2, this
growth arrest can be achieved at lower ligand concentrations,
hence larger halos are observed (Figure 9A). To test whether
the EGL-30(M244I) substitution produced a G-a protein that
was sensitive to RGS GAP activity, we constructed the
equivalent mutation, M362I, in the yeast G-a protein Gpa1.
The gpa1-M362I or wild-type GPA1 alleles were then ex-
pressed from a plasmid [43] in the background of a yeast
strain lacking both the RGS and wild-type G-a (sst2 gpa1).
When tested in the halo-formation assay, the sst2 gpa1 (p-gpa1-
M362I) and the sst2 gpa1 (p-GPA1) strains produced the same
diameter of halo, demonstrating that a functional G-a
protein is produced from the gpa1-M362I allele (Figure 9A
and 9B). The halo diameter was large, as expected in the
absence of the Sst2 RGS function. When Sst2 function was
returned to the two yeast strains (by expression of the SST2
gene from a second plasmid), halo diameter was reduced to
the same degree in the presence of the gpa1-M362I or the
wild-type GPA1 allele (Figure 9C and 9D). Thus, the yeast
gpa1-M362I allele produces a functional G-a protein that has
a normal response to the GAP activity of the RGS protein.
Since the equivalent G-a allele in C. elegans, egl-30(M244I), is
resistant to BMS-192364, a model in which the small molecule
acts as an RGS protein agonist is unlikely.
In the yeast halo formation assay, one qualitative difference
was apparent between the p-gpa1-M362I and the p-GPA1
strains, regardless of their RGS status. The halos produced by
the strain expressing Gpa1-M362I protein were less turbid
Figure 8. Models for Mechanism of Action
Four models of small-molecule action are presented. In model 1, the
small-molecule acts directly and uniquely as an antagonist of G-aq. In
model 2 the small-molecule acts directly and uniquely as an agonist of
the RGS protein’s GAP activity. In models 3 and 4 (our preferred models),
the small molecule interacts with both the RGS protein and G-aq, leading
to an increased affinity of RGS for the complex and/or an ‘‘abortive’’
complex (failure of G-aq to recycle). All models lead to reduction of the
GPCR signal through the activated G-aq.
DOI: 10.1371/journal.pgen.0020057.g008
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longer by a given dose of pheromone. The phenomenon of
growth resumption in the continued presence of the a–factor
ligand is called adaptation [42]; the gpa1-M362I allele is thus
hypo-adaptive. Interestingly, the M362I mutation affects a
region of Gpa1 where a number of hyper-adaptation alleles
have also been described [42,44,45] (Figure 10). These
mutations all affect amino acid residues on the surface that
is known to interact with downstream effectors of G-a [46].
Thus the C. elegans egl-30(M244I) mutation is likely to confer
resistance to compound by strengthening interactions with
effectors, rather than by insensitivity to RGS GAP activity.
This M/I substitution creates the ﬁrst hypo-adaptation allele
of G-a to be described.
A Genetic Test of the G-a Antagonist Model in C. elegans
The evidence presented so far suggested that the com-
pound could be acting on the G protein, the RGS protein or
potentially both. We devised a genetic test to attempt to help
distinguish between these possibilities. The experiment took
advantage of a putative activated egl-30 mutant that is
sensitive to the compound (unlike the egl-30(M244I) mutant
identiﬁed in the resistance screen). The egl-30(pk931) strain
has an Egl-c phenotype, indicative of constitutively activated
G-aq signaling. The R210Q substitution in egl-30(pk931)
affects a predicted key residue on the face of G-a that
interacts with the RGS protein. While there is no direct proof
that EGL-30(R210Q) is constitutively activated due to an
insensitivity to RGS GAP activity, a mammalian G-aq
mutation of the neighboring amino acid (Q209L) results in
both constitutive activation and insensitivity to RGS GAP
activity. The egl-30(pk931) strain was found to retain sensi-
tivity to BMS-192364 (Figure 4C). The ﬁnding that different
mutant alleles of the same gene have different sensitivities to
the compound suggests that the G-a protein, EGL-30, may be
directly involved in compound action. However, it cannot be
ruled out that the difference in sensitivity is due simply to a
difference in the degree of activation of the alleles.
What about the role of EAT-16? The assumption for the
following test is that if the G-aq protein is the sole component
interacting with the compound, then the presence or absence
of the RGS protein should not affect resistance/sensitivity to
the compound. Conversely, if presence of the RGS protein is
critical for compound activity, removing it (by mutation)
should confer resistance regardless of the status of the G-aq
subunit. Therefore, a double mutant strain containing the
compound-sensitive egl-30(pk931) allele and the RGS protein
loss-of-function eat-16(ad702) allele was constructed and
tested for small-molecule sensitivity. The eat-16(ad702); egl-
30(pk931) double mutant strain was found to be completely
resistant to BMS-192364 (Figure 4C), like the eat-16(ad702)
single mutant, implicating EAT-16 in compound action.
Figure 10. Amino Acid Substitutions in Mutants of the Yeast G-aq
Protein Gpa1
A theoretical three-dimensional structure of the yeast Gpa1 G-a protein
in complex with the Ste4 protein (G-b) is shown. The position of four
amino acid substitutions with phenotypes of interest is indicated by
circles. Two alpha helices are indicated by yellow highlighting of the
protein backbone. In higher eukaryotes, these helices are considered to
form the interface with G-aq downstream effector proteins. Three
mutations affecting adaptation to mating pheromone lie on this face:
E355K and E364K both hyper-adapt while the M362I allele described in
this work is hypo-adaptive. For reference, the position of a mutation
affecting sensitivity to RGS GAP activity, G302S, is also shown.
DOI: 10.1371/journal.pgen.0020057.g010
Figure 9. The Yeast gpa1-M362I Mutant Allele Causes a Hypo-Adaptation
Phenotype
Images show the growth of a monolayer of yeast cells around a paper
disc containing alpha factor, the peptide ligand for the Ste3 GPCR. A
zone of growth inhibition is visible as a ‘‘halo’’ around each disc.
(A) Yeast strain contains a wild-type G-aq gene (GPA1) and has a
chromosomal deletion of the SST2 gene, encoding an RGS protein.
(B) Yeast strain contains a wild-type G-aqg e n e(GPA1) and a
chromosomal deletion of the SST2 gene, but carries wild-type SST2 on
a plasmid.
(C) Yeast strain contains a mutant G-aq gene (gpa1-M362I) and has a
chromosomal deletion of the SST2 gene, encoding an RGS protein.
(D) Yeast strain contains a mutant G-aq gene (gpa1-M362I) and a
chromosomal deletion of the SST2 gene, but carries wild-type SST2 on a
plasmid.
DOI: 10.1371/journal.pgen.0020057.g009
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both the G-aq and RGS proteins interact with the compound.
Chemical Genetic and Biochemical Tests of the G-a
Antagonist Model in Mammalian Cells
To investigate the G-a antagonist model in mammalian
cells utilizing a better characterized G-aq allele, we overex-
pressed the mammalian G-aq-G188S mutant protein in Hek-
293 cells (construct courtesy of the Guthrie Research
Institute). The G-aq-G188S mutant protein requires ligand
stimulation, but is known to be resistant to subsequent
deactivation by RGS proteins, thus behaving as a constitutive
signaling molecule [12]. However, overexpression of G-aq-
G188S did not suppress the inhibitory effect of BMS-192364
upon carbachol-stimulated calcium ﬂux (Figure 7C). This
result (similar to the G-aq experiment in C. elegans above), also
fails to support a model where compound directly antago-
nizes G-aq.
Finally, we tested the compound’s direct biochemical
action on wild-type G-aq. We quantiﬁed binding of a radio-
labeled nonhydrolysable substrate (GTP-cS) to the G-a
protein downstream of the histamine H1 receptor (which is
G-aq coupled) [47] and the muscarinic receptor M4 (which is
G-ai/G-ao coupled) [48]. BMS-192364 displayed no signiﬁcant
activity in either assay, when performed in either agonist or
antagonist mode (unpublished data). These results suggest
that BMS-192364 does not directly affect GDP/GTP exchange
at G-aqo rG - ai/o.
Discussion
Here we investigate the mechanism of action for a novel
class of small molecules that are effective in assays for bladder
capacity and spontaneous bladder muscle contraction. We
have utilized C. elegans as a model system to investigate this
mechanism. Treatment of C. elegans with the compounds
produced a neuromuscular phenotype, i.e., decreased egg
laying, that correlated with the therapeutic activity in the
small-molecule series. The phenotype was used as the basis
for candidate gene analysis, and for a genetic resistance
screen. Strikingly, both approaches uncovered components
of the GPCR signaling pathway, a proven therapeutic target
in UI disease. The genetic screen uncovered dominant
mutations in two proteins (G-aq and RGS) that form an
important regulatory complex.
The results of subsequent genetic and biochemical analyses
were not consistent with models in which the compound acts
solely on either the G-a or the RGS protein (Figure 8, models
1 and 2). However, the results are consistent with models in
which the small molecule affects the RGS/G-aq complex and
results in the termination of GPCR signaling, as well as
alternative models involving adaptation responses to calcium
signals. If the small molecule increased the afﬁnity of the RGS
protein for the G-aq transition state, there would be an
increase in the rate of RGS protein GAP activity (Figure 8,
model 3). Alternatively, the small molecule could stabilize
RGS/G-a in an inactive complex, thus effectively acting as a
noncompetitive inhibitor of the G-aq signal (Figure 8, model
4). In either case, the small molecule could interact with both
the RGS protein and G-aq during the GTPase transition state.
Both of these mechanisms require the physical presence of
RGS protein for compound activity, and are consistent with
all of the available data.
In considering these alternative models based on inter-
action with the RGS/G-aq complex, we were struck by reports
concerning the small molecule brefeldin A and its effect on
the ARF1/Sec7 complex. The relationship between ARF1 and
Sec7 is partially analogous to that of G-aq and RGS: Arf1 is a
small GTPase of the Ras family, while Sec7 physically interacts
with Arfs to catalyze guanine nucleotide exchange (GEF
activity), thereby affecting downstream signal transduction.
The limitation to this analogy is that Sec7 has GEF activity
whereas RGS proteins have GAP activity, thus they represent
different stages of the guanine nucleotide cycle. However, in
both cases it is thought that the reactions involving guanine
nucleotide require formation of docking intermediates with
the GTPase. Brefeldin A binds to and stabilizes the Arf1-GDP-
Sec7 domain protein complex (the ﬁrst intermediate on the
nucleotide exchange reaction pathway). It is thought that
brefeldin A prevents an important region of Arf1-GDP from
reorganizing. Brefeldin A activity is also sensitive to
mutations in both Sec7 and Arf1. Thus far our efforts to
prove a direct effect of the compounds on an RGS/G-Protein
complex have not been successful. These efforts have greatly
been hampered by the difﬁculty in obtaining puriﬁed, active
G-aq protein, and the very limited solubility of the
compounds in immunoprecipitation experiments.
In addition to the models above, others remain possible.
RGS proteins have been shown to interact with proteins
other than G-proteins. Alternative (or additional) interaction
partners include kinases, G-b5, and GPCRs. Recent unpub-
lished data from our group suggests that these componds
have a disruptive effect on an RGS protein/GPCR interaction
within cells (KF, personal communication). Disruption of this
interaction could conceivably result in additional free RGS.
However, the signiﬁcance of this disruption, and the
consequences of it in the context of G-protein signaling,
remains to be further investigated.
These studies have uncovered a novel set of mutants that
will provide signiﬁcant insight into G-a and RGS protein
function. Our analysis of the compound-resistant G-a M244I
allele using a yeast assay indicates that it causes increased
sensitivity to continued presence of ligand (hypo-adaptation).
While hyper-adaptation alleles that affect the same region of
the protein have been uncovered, we believe this is the ﬁrst
hypo-adaptation allele to be described for G-a.H y p o -
adaptation alleles of the yeast G-b protein Ste4 have been
identiﬁed as suppressors of a GPA1 hyper-adaptation allele
[44]. Since hypo- and hyper-adaption mutations of hetero-
trimeric G-protein components affect their sensitivity to
GPCR agonist–antagonist activity in genetic model systems,
variations of these proteins in patient populations may be
relatedtodifferential responses toGPCRmodifying therapies.
It is also noteworthy that we identiﬁed a dominant resistant
mutation in EAT-16 (E158K) that did not affect the well-
deﬁned RGS, GGL, or DEP domains (Figure 4B). Existing
crystal structures of RGS complexes are limited to the RGS
domain itself, and the role of other regions of the protein is
not as clear. Previous work has implicated the region of EAT-
16 containing the E158K mutation in determining speciﬁcity
of the RGS/G-a interaction, and in the binding and stabilizing
of RGS by G-b5 [24]. It is possible that the EAT-16 E158K
mutation results in an inability to bind G-b5 and consequent
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function phenotype.
In this work, we have used an unusual combination of
technologies: small-molecule screens, genetic analysis in two
model systems, and biochemical assays. The relevance of the
pathway and targets suggested by the model system genetics
was validated by assays on mammalian systems. While the
exact mechanism of action of these compounds remains
under investigation, it is certain that these small molecules
have a unique action downstream of muscarinic GPCRs, and
that they function by limiting G-a signaling. The discovery of
such compounds, as well as the unique RGS and G-a
mutations uncovered here, has implications for GPCR activity
modifying therapies. This work also supports the notion that
small molecules affecting pathways downstream of GPCR
function in novel ways, and could represent potential new
therapies or biomarkers for diseases characterized by
inappropriate activation of GPCR signaling.
Materials and Methods
All experiments that involved collecting and processing animal
tissue samples were performed using animal test methods approved
by the Bristol-Myers Squibb Institutional Animal Care and Use
Committee, and in accordance with the Guide for the Care and Use
of Laboratory Animals as adopted and promulgated by the National
Institutes of Health.
Rat whole bladder ex vivo model. The model used for functional
experiments was a modiﬁed version of that described in 1986 by
Malkowicz et al. [49]. Brieﬂy, a female rat (250–350 g) (Harlan Sprague
Dawley, Indianapolis, Indiana, United States) was sacriﬁced by
decapitation. The bladder was excised, cleaned of connective tissue,
and the ureters were tied. The bladder was catheterized at the urethral
openingand mounted in a 50-ml organbath containing normal Kreb’s
buffer (composition in mM: NaCl 118.4, KCl 4.7, KH2PO4 1.2, MgSO4
1.3, CaCl2 1.8, Glucose 10.1, NaHCO3 25, gassed with 95% O2/5% CO2,
37 8C). The bladder was infused with normal Kreb’s buffer at 0.05 ml/
min for 30 min to a maximum volume of 1.5 ml. The pressure
developed in the bladder during the infusion was measured using a
pressure transducer (model P23XL, Ohmeda, Norcross, Georgia,
United States) and an AcKnowledge data acquisition system (MP100WS,
Biopac Systems, Goleta, California, United States). At the end of
infusion the bladder was allowed to empty and the volume of
‘‘spontaneous’’ bladder emptying was measured. Carbachol (1 and 10
lM) was added to the bath to induce complete bladder emptying
(unpublished data). Bladders were subjected to a series of three
infusions: 1) a ‘‘conditioning’’ infusion with normal Krebs followed by
a 1-h recovery period; 2) a ‘‘control’’ infusion followed by 1-h
incubation with BMS-195270 or vehicle (in paired controlled experi-
ments); and 3) a ﬁnal infusion in the presence of BMS-195270 or
vehicle. Statistical analysis of the data was performed using an
unpaired t-test; p , 0.05 was considered signiﬁcant (GraphPad InStat,
version3.05,GraphPadSoftware,SanDiego,California,UnitedStates).
Caþþ ﬂux assays. HEK293 cells or primary human bladder cells
were seeded at a density of 5 3 10
4 per well on Poly-D-lysine–coated
96-well white/clear Biocoat microtiter plates (Becton-Dickinson,
Bedford, Massachusetts, United States) overnight in DMEM þ10%
FBS. Cells were washed 33in 100-uL Kreb’s buffer (NaCl 118 mM, KCl
4.7 mM, MgSO4 1.2 mM, KH2pO4 1.2 mM, NaHCO3 4.2 mM, D-
Glucose 11.7 mM, CaCl2 1.3 mM, Hepes [pH 7.4] 10 mM). Cells were
equilibrated (‘‘loaded’’) with 4 uM Fluo-4 (Molecular Probes, Eugene,
Oregon, United States) in Kreb’s buffer containing 0.08% (wt/vol)
Pluronic F-127 and 0.25 mM sulﬁnpyrazone for 1 h with the plate
covered in foil. Cells were washed 23 in 100-uL Kreb’s buffer
containing 0.5% BSA and 0.25 mM sulﬁnpyrazone. The BMS
compound stocks were made up in DMSO and diluted to working
concentrations in Kreb’s buffer containing 0.5% BSA and 0.25 mM
sulﬁnpyrazone. 100uL of either the test compound or vehicle was
added to the wells and the plate incubated for 15 min at room
temperature. The [Ca
2þ]i signal was evoked by addition of histamine
or carbachol at the concentrations indicated in ﬁgure legends. Two
detection systems were used and yielded similar results. In system
one, Fluo-4 was excited at 488 nm and ﬂuorescence emission at 510
nm was determined simultaneously from multiple wells in a time-
resolved mode (1 Hz frequency) using a ﬂuorometric plate reader
(FLIPR, Molecular Devices, Sunnyvale, California, United States).
Relative ﬂuorescence intensity was used as indication of evoked
[Ca
2þ]i signal. Data acquisition and preliminary analysis was
performed using FLIPR software (Molecular Devices). Alternatively,
Fluo-4 was measured with the 488 excitation/535 emission ﬁlter set on
a well-by-well basis using a Wallac Victor2 ﬂuorometer (PerkinElmer,
Boston, Massachusetts, United States). In both systems, a baseline
ﬂuorescence was measured at each second for 5 s, followed by agonist
injection. Subsequent readings were taken at each second up to 60 s
and then every 2.5 s up to 75 s. The EC50s were obtained and graphs
generated using GraphPad Prism software (GraphPad Software). The
EC50 for BMS 195270 in these assays was 2 lM and for BMS-192364
was 9 lM.
For experiments with niguldipine pretreatment, cells were loaded
with Fluo-4 dye as described above. Treatment with 100 lM
niguldipine (IC50 75 nM, Sigma-Aldrich, St. Louis, Missouri, United
States) was initiated 15 min prior to addition of the small molecules
under test. Control wells received an equal concentration of vehicle.
The cells were then treated with either test small molecules or vehicle
for 15 min, followed by stimulation with 100 lM carbachol.
For experiments with pertussis toxin, cells were pretreated for 24 h
in complete media with 150 ng/ml pertussis toxin (Calbiochem, San
Diego, California, United States) or a vehicle control. Cells were then
washed 33in media and loaded with Fluo-4 as described above. Cells
were then treated with either test small molecules or vehicle for 15
min followed by stimulation with 100 lM carbachol.
Radio-ligand binding assays. All radio-ligand–binding and GTP-cS
assays were carried out by MDS Pharma Services, Taiwan. M1–M5
muscarinic receptor assays were carried out essentially as in [28,29]:
recombinant M1–M5 were expressed in CHO cells and were used in a
modiﬁedTris-HCLbuffer(pH7.4).A16-mgaliquotwasincubatedwith
0.8 nM f
3HgN-methylscopolamine for 120 min at 25 8C. Nonspeciﬁc
binding was estimated in the presence of 1 lM atropine. Membranes
were ﬁltered and washed. The ﬁlters were counted to determine the
speciﬁcally bound
3H. BMS compounds were tested at 10 lM.
Calcium channel–binding assays were carried out essentially as in
[30,34]. Brieﬂy, frontal lobe brains of male Wistar-derived rats
weighing 175 g were used to prepare N- or L-type calcium channels
in modiﬁed Tris-Hcl buffer (pH 7.4). A 40-ug aliquot was incubated
with either 10 pm f
125Igx-conotoxin GVIA (N-type channel inhibitor)
for 30 min at 4 8C, or a 0.5 mg aliquot was incubated with 2 nM f
3Hg
diltiazem for 180 min at 4 8C. Nonspeciﬁc binding was estimated in
the presence of either 100nm x-conotoxin GVIA or 10 lM diltiazem.
Membranes in each case are ﬁltered and washed with the ﬁlters
subsequently counted for radioisotope. BMS compounds were
screened at 10 lM.
M4 and H1 GTP-cS assays were carried out under standard
conditions in both agonist and antagonist modes [47,48]. Brieﬂy,
human muscarinic receptor M4 was expressed in Sf9 cells. Test
compound was pre-incubated with 0.2 mg/ml membranes and 3 lM
GDP for 20 min at 25 8C in modiﬁed HEPES buffer (pH 7.4). SPA
beads were added for another 60 min at 30 8C. The reaction was then
initiated by addition of 0.3 nM f
35SgGTP-cS for 15 min. BMS
compounds were tested at 10, 1, 0.1, and 0.001 lM for their ability to
increase GTP-cS binding relative to 10 lM McN-A-343 (indicating
possible agonist activity), or to inhibit an increase in binding
rendered by 1 lM dopamine. For histamine H1 assays, the receptor
was expressed in CHO cells. BMS compounds were pre-incubated
with 0.022 mg/ml receptor and 1 lM GDP in modiﬁed HEPES buffer
(pH 7.4) for 20 min at 25 8C, SPA beads were added for another 60
min at 30 8C. The reaction was then initiated by addition of 0.3M
f
35SgGTP-cS for 30 min. BMS compounds were tested at 10, 1, 0.1,
and 0.001 lM for their ability to increase or decrease GTP-cS binding
relative to 10 lM histamine, indicating possible agonist or antagonist
activity.
Phenotypic and genetic analysis of C. elegans. C. elegans strains were
cultured and maintained according to standard procedures. All
strains were assayed at 20 8C unless otherwise indicated. Sequence
analysis showed that the eat-16(ad702) allele carries an AG ! AA
mutation in the splice acceptor site before the fourth exon, which
results in early termination before the RGS domain that interacts
with G-aq. This allele shows no additional phenotypes when placed
opposite a chromosomal deﬁciency that deletes the entire RGS
protein coding region; i.e., it behaves as a null allele for eat-16.
Small-molecule treatment of C. elegans. Treatment of C. elegans with
the small molecules was conducted as follows: a solution of the small
molecule in DMSO was mixed with a slurry of killed bacteria (strain
OP50, taken through multiple freeze–thaw cycles) to twice the desired
ﬁnal concentration. Adult wild-type or mutant hermaphrodites
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mixed with the small-molecule/bacteria slurry in a 1:1 ratio, and
plated on peptone-free NGM plates. The ﬁnal DMSO concentration
did not exceed 1%. At 1, 2, 4, 8, and 16 h of treatment, worms were
observed and assessed for behavioral and visible defects.
For egg-laying assays, adults were treated overnight with the small
molecule. Approximately thirty animals were then loaded onto agar
pads made on glass slides, and examined under Nomarski optics.
Animals were scored as egg-laying defective if they contained
developing (‘‘comma stage’’) embryos.
EMS mutagenesis/screening of C. elegans. EMS mutagenesis was
conducted according to standard procedures [50]. Brieﬂy, Bristol N2
hermaphrodites of L4 stage were treated with 0.25% EMS (Sigma-
Aldrich) in M9 for 4 h at 20 8C. Worms were washed 43in M9 media,
and plated onto seeded NGM plates. Staged collections were taken of
the F1 generation, and these were plated onto NGM plates at either
20 8Co r1 58C. Staged collections of the F2 generation were plated
onto NGM plates and allowed to grow until adulthood. These adults
were then collected and treated with small molecule. After an
overnight treatment with the test compounds, animals that were not
visibly egg-laying defective were isolated and retested for resistance
to small molecule.
Characterization of alleles from C. elegans mutants. Mutant
hermaphrodites were crossed to males of the polymorphic strain
CB4856 (Hawaiian isolate). Recombinant homozygous mutants in the
F2 generation were selected by their visible phenotype and assayed
for SNPs. Genotyping of SNP markers was performed using standard
methods and employed SNPs identiﬁed either through the Wash-
ington University SNP project or privately at Exelixis. The map data
generated was as follows:
egl-30(ep271): ChrI;  17.9 cM to  5.53 cM (;1700 kb)
ep272: Chr I;  10.31 cM to  8.76 cM (;150 kb)
eat-16(ep273): ChrI; 2.63 cM to 4.4 cM (;2 Mb)
goa-1(ep275): ChrI; 2.03 cM to 3.74 cM (;2.6 Mb)
For the eat-16(ep273), egl-30(ep271), and goa-1(ep275) alleles, the
identity of the mutant gene was conﬁrmed by sequence analysis of
PCR products templates upon genomic DNA from the mutant strains.
Sequencing of PCR products was performed according to manufac-
turer’s instructions (Applied Biosystems, Foster City, California,
United States).
Construction and analysis of yeast strains. Centromeric vectors
from the pRS series [43] were used to provide GPA1 and SST2 gene
functions as follows. A 2.8-kb PCR fragment containing the wild-type
yeast GPA1 gene and promoter was ampliﬁed from genomic DNA
using primers CGGGATCCAAGAGCCCAAGTATGTAA and
CGGGATCCTCATATAATACCAATTTTT and cloned into pCR.TO-
PO2.1 (Invitrogen, Carlsbad, California, United States). A BamHI
fragment containing the amplicon was moved to pJC72 (pRS415 with
the PHO5 transcription terminator) to create plasmid pJC73. Site-
directed mutagenesis of pJC73 using the Quikchange system (Stra-
tagene, La Jolla, California, United States) with the oligonucleotide
primers GGATGAAAGAGTGAACAGAATTCATGAATCAA
TAATGCTATTTG and CAAATAGCATTATTGATTCAT
GAATTCTGTTCACTCTTTCATCC generated plasmid pJC74, con-
taining the gpa1-M362I substitution. The full GPA1 gene sequence was
conﬁrmed in pJC73 and pJC74. To provide Sst2 function, a 2-kb
amplicon containing the coding sequence was generated from
genomic DNA using primers GAGGATCCATGGTGGATAAAAA
TAGGACG and CGGTCGACTTAGCACTTTTCTTGGATTTC. The
amplicon was cloned into p416-TEF (pRS416 with the TEF1 promoter
sequence and the CYC1 terminator) to create plasmid pJC156.
Strain Y87 (MATa gpa1 sst2 leu2 ura3 his3) was isolated from a
meiotic tetrad that showed 2:2 segregation of G418-resistance from a
cross between RG6055 and RG16602 (Research Genetics, Huntsville,
Alabama, United States). Y87 has the slow growth phenotype
expected of a gpa1 mutant; this phenotype was complemented
following transformation with pJC73 or pJC74. For halo assays, a
suspension of yeast cells (OD600 0.3) was poured onto solid yeast
growth medium and the excess liquid drained. Medium was synthetic
complete minus leucine for pJC73 or pJC74; synthetic complete
minus uracil and leucine for pJC73 or pJC74 with pJC156. 10 llo fa2 -
mg/ml solution of a-factor in water was placed on a 7-mm glass ﬁber
disc (Schleicher and Schuell Bioscience, Keene, New Hampshire,
United States) at the center of the plate. Plates were incubated at 30
8C for 24 h before photography.
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